CLIN CHEM LAB MED:超离心法测定血浆中脂蛋白颗粒的重复性和再现性如何?

2020-02-12 MedSci MedSci原创

由于超离心技术对脂蛋白颗粒(包括主要类和亚类)进行定性是非常必要的。然而,目前仍需要取代非常劳动密集型的核磁共振的方法。一种解决方案是校准基于核磁共振的快速预测模型,但关于核磁共振校准所需的核磁共振响应方法的可靠性在很大程度上被忽视。

由于超离心技术对脂蛋白颗粒(包括主要类和亚类)进行定性是非常必要的。然而,目前仍需要取代非常劳动密集型的核磁共振的方法。一种解决方案是校准基于核磁共振的快速预测模型,但关于核磁共振校准所需的核磁共振响应方法的可靠性在很大程度上被忽视。

在不同主要类别和子类别的25个重复的新鲜血浆样本和42个健康个体的冷冻质量控制(QC)合并血浆样本中,这项研究为25种重复血浆样品的不同主要类别和亚类别中的各种基于UC的脂质测量(胆固醇,甘油三酸酯[TGs],游离胆固醇,磷脂,载脂蛋白[apo] A1apoB)提供了全面的可重复性和重现性研究。

研究结果显示和,所有类别的胆固醇、apoA1apoB测量结果均具有很高的重复性(类内相关系数[ICC]: 92.93%-99.54%)。主要类和亚类中的游离胆固醇和磷脂浓度以及高密度脂蛋白(HDL)、高密度脂蛋白(HDL)亚类和低密度脂蛋白(LDL)亚类中的TG浓度显示出较差的重复性(ICC: 19.21%-99.08%),这是由于UC和试验限制期间引入的低浓度、可变性造成的。在冰冻的QC样品中,胆固醇、apoA1apoB浓度的重复性优于游离胆固醇、磷脂和TGs浓度。

本研究表明,对于某些亚类中接近或低于检测限(LOD)LPPs测量,以及使用冷冻样本,结果可重复性和再现性变差。此外,我们还发现,与UC结合的游离胆固醇和磷脂的分析方法具有不同的重复性和重现性。在校准未来基于NMR的模型时,需要考虑所有这些因素。

原始出处:

Sandra Monsonis-Centelles,Huub C.J. Hoefsloot,Repeatability and reproducibility of lipoprotein particle profile measurements in plasma samples by ultracentrifugation

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1662319, encodeId=d3fc166231945, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Wed Oct 21 17:08:00 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751560, encodeId=01881e515607b, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Tue Jan 26 03:08:00 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424768, encodeId=4b0f1424e689a, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610242, encodeId=d236161024234, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2020-10-21 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1662319, encodeId=d3fc166231945, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Wed Oct 21 17:08:00 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751560, encodeId=01881e515607b, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Tue Jan 26 03:08:00 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424768, encodeId=4b0f1424e689a, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610242, encodeId=d236161024234, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2021-01-26 珙桐
  3. [GetPortalCommentsPageByObjectIdResponse(id=1662319, encodeId=d3fc166231945, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Wed Oct 21 17:08:00 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751560, encodeId=01881e515607b, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Tue Jan 26 03:08:00 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424768, encodeId=4b0f1424e689a, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610242, encodeId=d236161024234, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1662319, encodeId=d3fc166231945, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Wed Oct 21 17:08:00 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751560, encodeId=01881e515607b, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Tue Jan 26 03:08:00 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424768, encodeId=4b0f1424e689a, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610242, encodeId=d236161024234, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 14 14:08:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]

相关资讯

eLife:震撼推出5篇重复性研究,直指**研究可重复性差

1月19日,eLife杂志在线出版了5篇研究论文,这些研究直指过去几年里肿瘤生物学领域广受瞩目的部分研究成果的可重复性非常差。 背景介绍: 2013年,一位名叫Elizabeth Iorns的80后女性肿瘤生物学家(University of Miami Miller School of Medicine助理教授)发起了一项“癌症生物领域重复性工程”(Reproducibility

Nature:研究揭示重复性脑创伤典型特征

近日,英国研究人员描述了一种由重复性头部创伤(如运动伤害)引起的神经退行性疾病中的蛋白质组装。慢性创伤性脑部病变(CTE)的特征是tau 蛋白累积聚合,类似阿尔茨海默病一样。这项新研究表明,虽然影响这两种疾病的是同一种tau 蛋白,但CTE 中的tau 组装与阿尔茨海默病中的略有不同。以上发现证明,tau 组装的细微差异定义了不同的神经退行性疾病。

新工具可计算生物医学论文可重复性得分

1 月 19 日公布的一个新的在线工具可通过分析已发表论文的引文数量,衡量该论文可再现性。